Immunomic Therapeutics

118 articles about Immunomic Therapeutics

• Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

  2/6/2019

  Immunomic Therapeutics, Inc. announced that the company has granted Japanese animal health company, ZENOAQ an exclusive license to develop and commercialize its investigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies.

• Immunomic to Present at the 2019 BIO CEO & Investor Conference

  1/24/2019

  Immunomic Therapeutics announced today that its’ founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City.

• Immunomic Therapeutics to Present at the 2018 World Vaccine & Immunotherapy Congress

  11/15/2018

  Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy Congress West Coast, being held November 28-29 in San Diego, CA.

• Immunomic Therapeutics Scientist to Present at the Society for NeuroOncology 2018 Annual Meeting

  11/7/2018

  On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual Meeting in New Orleans.

• Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R & D Summit

  10/28/2018

  Discussion of lysosomal targeting technology as applied in cancer immunotherapy

• Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit

  10/26/2018

  Discussion of lysosomal targeting technology as applied in cancer immunotherapy

• Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference

  10/23/2018

  To Discuss UNITE Technology Application in Oncology

• Immunomic Therapeutics to Present at the 2018 BIO Investor Forum

  10/11/2018

  Immunomic Therapeutics, Inc. announced today that the company will present at the 2018 BIO Investor Forum being held in San Francisco, CA on October 17-18.

• Immunomic Therapeutics CEO to Join Panel at 18th Annual Biotech in Europe Forum

  10/3/2018

  Panel to Highlight Advanced Therapeutics for Oncology

• Tomorrow: Immunomic Therapeutics CEO at Outsourcing in Clinical Trials Mid-Atlantic

  10/1/2018

  ITI Founder & CEO will discuss new developments in cancer immunotherapy

• Immunomic Therapeutics CEO to Present at Precision Medicine World Conference (PMWC): Emerging Therapeutics Showcase

  9/24/2018

  Presentation to Highlight UNITE Potential Capabilities in Immuno-Oncology

• Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech18 Conference

  9/19/2018

  Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy

• Immunomic Therapeutics to Present at the 2018 China BioMed Innovation and Investment Conference

  9/18/2018

  Presentation to Highlight UNITE technology application to oncology

• Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

  8/29/2018

  Presentation to Highlight the Challenges of Viral Targets in Cancer

• Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum

  4/19/2018

  Panel Will Discuss Strengths in BioHealth Immunotherapies

• ITI Senior Director of Corporate Development to Participate in an All Women’s Leadership Panel Discussion and Dinner at ISPE’s First Women in Pharma Event

  3/22/2018

  Immunomic Therapeutics Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD.

• Immunomic to Participate at 2018 BIO CEO & Investor Conference with Presentation and Panel Discussion

  2/12/2018

  Immunomic announced today that the company will participate at the 2018 BIO CEO & Investor Conference in two events:

• ITI Senior Director of Corporate Development to Present on LAMP-Vax Investigational Technology at Immuno-Oncology Frontiers World

  1/23/2018

  Tomorrow, Immunomic Therapeutics Senior Director of Corporate Development Sia Anagnostou will present at Phacilitate’s Immuno-Oncology Frontiers World in Miami.

• Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board

  12/13/2017

  Dr. Pardoll is a world-renowned cancer researcher in the field of immuno-oncology.

• Immunomic Therapeutics’ Founder Appointed to Maryland Life Sciences Advisory Board

  11/29/2017

  The LSAB was created in 2007 to assist in maintaining Maryland’s strong presence in the life sciences industry.